These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 22804570)

  • 1. The use of agonistic anti-CD40 therapy in treatments for cancer.
    Khong A; Nelson DJ; Nowak AK; Lake RA; Robinson BW
    Int Rev Immunol; 2012 Aug; 31(4):246-66. PubMed ID: 22804570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody.
    Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ
    Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K; Teramoto K; Ozaki Y; Sawai S; Tezuka N; Ishida H; Kajino K; Fujino S; Yamauchi A; Taguchi O; Kannagi R; Yokomise H; Ogasawara K
    Oncol Rep; 2007 Apr; 17(4):895-902. PubMed ID: 17342333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Agonistic anti-CD40 antibody therapy is effective against postoperative cancer recurrence and metastasis in a murine tumor model.
    Khong A; Brown MD; Vivian JB; Robinson BW; Currie AJ
    J Immunother; 2013 Sep; 36(7):365-72. PubMed ID: 23924788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials.
    Hassan SB; Sørensen JF; Olsen BN; Pedersen AE
    Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):96-104. PubMed ID: 24555495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects.
    Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells.
    Honeychurch J; Glennie MJ; Illidge TM
    Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD40 ligation converts TGF-beta-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones.
    Zhang X; Kedl RM; Xiang J
    Biochem Biophys Res Commun; 2009 Feb; 379(4):954-8. PubMed ID: 19135981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.
    Hunter TB; Alsarraj M; Gladue RP; Bedian V; Antonia SJ
    Scand J Immunol; 2007 May; 65(5):479-86. PubMed ID: 17444959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
    Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
    J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses.
    Chen M; Ouyang H; Zhou S; Li J; Ye Y
    Cell Immunol; 2014 Feb; 287(2):91-9. PubMed ID: 24487032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
    Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
    Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.
    Ge Y; Xi H; Zhang XG
    Biomed Pharmacother; 2010 Sep; 64(7):487-92. PubMed ID: 20382498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help.
    French RR; Chan HT; Tutt AL; Glennie MJ
    Nat Med; 1999 May; 5(5):548-53. PubMed ID: 10229232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects for CD40-directed experimental therapy of human cancer.
    Tong AW; Stone MJ
    Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process.
    Mauri C; Mars LT; Londei M
    Nat Med; 2000 Jun; 6(6):673-9. PubMed ID: 10835684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells.
    Kikuchi T; Miyazawa N; Moore MA; Crystal RG
    Cancer Res; 2000 Nov; 60(22):6391-5. PubMed ID: 11103803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cancer treatment by comprehensive regulation of anti-tumor immune network].
    Kawakami Y
    Nihon Rinsho; 2010 Jun; 68(6):1094-9. PubMed ID: 20535961
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.